课题基金 / 基金详情

Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity

Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity
具有优化安全性和免疫原性的 RSV 减毒活疫苗
批准号:
9133254
负责人:
Mark E. Peeples
金额:
$148.92万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-27 至 2020-01-31
关键词:

项目摘要

项目成果

Mark E. Peeples的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants and young children, however no vaccine is currently available. The overall objective of this grant is to develop optimal live attenuated RSV vaccine candidate(s). The significance of this P01 is that it brings together a multidisciplinary group of investigators to leverage a novel observation that infants with severe RSV disease display a pattern of inadequate (or suppressed) immune responses. The grant will simultaneously attack this problem on multiple fronts by developing a vaccine with increased immunogenicity, attenuating the virus in a novel, `tunable' way, improving its yield in cell culture to improve vaccine production, and using gene expression and new antibody detection tools for analysis of the immune response in order to predict vaccine effectiveness and safety. These candidates will be tested first in vitro in primary well differentiated human airway epithelial cultures. Vaccine candidates with the desired characteristics will be selected for testing in vivo in cotton rats for their attenuation and their ability to induce a `safe' host response (similar to natural mild RSV disease in infants), and potent neutralizing antibodies to RSV. Combination mutants will be recycled through this system, resulting in the selection of one optimal vaccine candidate and rank order of excellent backups. By integrating the host response to RSV infection with modifications of the virus that improve these responses, the four projects of this P01 will synergize to develop an optimized live attenuated RSV vaccine candidate ready for testing in human primates and possibly clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism of Respiratory Syncytial Virus Fusion
Mechanism of Respiratory Syncytial Virus Fusion
Mechanism of Respiratory Syncytial Virus Fusion
Mechanism of Respiratory Syncytial Virus Fusion
国内基金
海外基金
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
  • 批准号:
    22007020
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    周志
  • 依托单位:
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2019
  • 负责人:
    周志
  • 依托单位:
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
  • 批准号:
    81473017
  • 项目类别:
    面上项目
  • 资助金额:
    66.0万元
  • 批准年份:
    2014
  • 负责人:
    孙涓
  • 依托单位:
用于识别癌细胞A549的磁共振和荧光双功能探针的研究